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Circulating microRNAs (miRNAs) have emerged as
candidate biomarkers of various diseases and condi-
tions including malignancy and pregnancy. This ap-
proach requires sensitive and accurate quantitation of
miRNA concentrations in body fluids. Herein we re-
port that enzyme-based miRNA quantitation, which is
currently the mainstream approach for identifying
differences in miRNA abundance among samples, is
skewed by endogenous serum factors that co-purify
with miRNAs and anticoagulant agents used during
collection. Of importance, different miRNAs were af-
fected to varying extent among patient samples. By
developing measures to overcome these interfering
activities, we increased the accuracy, and improved
the sensitivity of miRNA detection up to 30-fold. Over-
all, the present study outlines key factors that prevent
accurate miRNA quantitation in body fluids and pro-
vides approaches that enable faithful quantitation of
miRNA abundance in body fluids. (J Mol Diagn 2012,
14:71–80; DOI: 10.1016/j.jmoldx.2011.09.002)
MicroRNAs (miRNAs) are small non-coding RNA se-
quences of approximately 19 to 22 nucleotides that modu-
late the activity of specific mRNA targets in development,
differentiation, or disease, typically by compromisingmRNA
stability or interfering with translation (reviewed by Almeida
et al,1 Corcoran et al,2 Brase et al,3 Zen and Zhang,4 and
Kosaka et al5). Recently, miRNAs circulating in body
fluids, and in blood serum in particular, have emerged as
promising markers of disease and other processes (re-viewed in references1–5). This application raises the need
to accurately identify and quantitate miRNAs in samples
collected from patients.
The mainstream approach to identification and quan-
tification of miRNAs uses quantitative RT-PCR (RT-
qPCR). With RT-qPCR, changes in plasma and serum
miRNA profiles have been reported to reflect various
physiologic and pathologic conditions including diagnos-
tic and prognostic values for colorectal, breast, gastric,
lung, oral, ovarian, pancreatic, and prostate cancers and
for leukemia and lymphoma1–5 and other diseases and
conditions.6–9 The increasing use of cell-free circulating
miRNA for diagnostic and prognostic purposes, as for any
such marker, requires assurance that the measured con-
centration represents the actual amount in the samples.
Such assurance is often lacking.10 The problem is exacer-
bated by the common assumption that a protocol devel-
oped for one study is applicable to other studies.11 Overall,
few methods12 and improvements13 have been offered,14
and commonly used approaches lack required accuracy.15
The objective of the present study was to standardize
and optimize miRNA detection for biomarker studies. We
quantified two miRNAs that are implicated in distinct pro-
cesses. One was miR-16, which acts as a tumor suppres-
sor, is UV-inducible, is p53-regulated, and is deregulated
or lost in some cancers.16 MiR-16 has also been used to
normalize quantitation of circulating miRNAs in breast
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been implicated in pregnancy, other conditions, and ma-
lignant disease.6,20,21 Devising reliable approaches for
accurate quantitation of circulating miRNAs is important
for assessment of their potential as biomarkers.
Materials and Methods
Collection of Blood Samples
Fresh blood samples (5 mL) were either collected from
healthy adults, received from the Susan G. Komen Foun-
dation for the Cure Tissue Bank at the IU Simon Cancer
Center (Indiana University, Indianapolis, IN), or supplied
by Jeffrey Martin, MD of the AIDS Cancer and Specimen
Resource (University of California, San Francisco, CA).
Blood was collected in Vacutainer tubes (BD Diagnos-
tics, La Jolla, CA) containing 10 mL heparin (sodium
heparin, 143 USP units), 4.0 mL EDTA (EDTA, 7.2 mg),
4.5 mL sodium citrate (sodium citrate, 0.105 mmol/L), or
2 mL sodium fluoride and potassium oxalate (NaF/KOx, 5
mg/4 mg). Serum (7.5 mL) was collected in BD SST
Vacutainer tubes (BD Diagnostics). Plasma was sepa-
rated from red blood cells promptly to prevent loss of com-
ponents22 or hemolysis.23 Blood was allowed to coagulate
for 15 minutes at room temperature before prompt centrif-
ugation. The study was approved by the Rosalind Franklin
University of Medicine and Science institutional review
board under protocols 004 and 005 PATH, and all donors
provided written consent.
Processing of Blood Samples
Fresh plasma and serum were obtained by centrifugation
of blood samples at 200  g for 15 minutes at 4°C.
Supernatants were removed and collected in 15-mL poly-
propylene tubes. The plasma was centrifuged twice at
800  g for 15 minutes at 4°C to obtain cell-free plasma.
After the second centrifugation, supernatants were col-
lected and passed through 0.45-m pore-size filters (Pall
Corp., Port Washington, NY). Plasma and serum were
divided into 200-, 50- and 10-L samples, and total vol-
umes were adjusted to 200 L using water. A synthetic
RNA (SYNTH, formerly INT,18 250 fmol/L) was added,
and samples were analyzed immediately or were
flash-frozen.
Heparinase Treatment of Samples
Digestion of plasma samples using heparinase I (H2519;
Sigma-Aldrich Corp., St. Louis, MO) was performed ac-
cording to the manufacturer’s protocol, as follows. Hepa-
rinase I (55 units) was dissolved at 1 mg/mL in 20 mmol/L
Tris-HCl (pH 7.5), 50 mmol/L NaCl, 4 mmol/L CaCl2, and
0.01% bovine serum albumin, and was added to a final
concentration of 143 USP units per 10 mL of sample,
which is expected to nearly completely remove hepa-
rin.24 All digestions were performed for 1 hour at room
temperature, and heparinase was removed using phenol-
chloroform extractions.Post-Collection Treatment of Samples Using
NaF/KOx
NaF (S-6776; Sigma-Aldrich Corp.) and KOx (P5311;
Aqua Solutions, Deer Park, TX) were used for the exper-
iments. Five milliliters blood was collected in NaF/KOx
Vacutainer tubes containing 5 mg NaF and 4 mg KOx,
effecting a final concentration of 1 g/L NaF and 0.8
g/L KOx (1X). Therefore, 50-L serum and EDTA sam-
ples were supplemented with NaF/KOx at 8X (8 g/L
NaF/6.4 g/L KOx), 4X (4 g/L NaF/3.2 g/L KOx),
2X (2 g/L NaF/1.6 g/L KOx), 1X (1 g/L NaF/0.8
g/L KOx), and 0.5X (0.5 g/L NaF/0.4 g/L KOx),
as indicated.
Determination of Exosomal miRNA Stability in
Blood Plasma and Whole Blood
Blood was collected in EDTA Vacutainer tubes. Half was
processed to produce cell-free plasma, and the other half
was left intact. To test the stability in blood of miRNAs
released from cells in culture, aliquots of the plasma and
serum were supplemented with exosomal miRNA of BC3
cells and incubated for the indicated time at 10°C in a
continuously revolving tube rotator.
RNA Isolation
SDS was added to 200-L samples of plasma or serum
for a final concentration of 0.5% where indicated. This
preparation was extracted using 500 L or 1 mL TRIzol
LS reagent (Invitrogen Corp., Carlsbad, CA) and incu-
bated for 10 minutes at room temperature followed by
100 or 200 L chloroform. The mixture was centrifuged at
12,000  g for 16 minutes, and the aqueous layer was
transferred to a new tube. Where indicated, this prepa-
ration was extracted one to three times using acidic phe-
nol/chloroform (0966; Amresco Corp., Solon, OH). The
resulting aqueous phase was transferred to a new tube
and applied to a PureLink miRNA isolation kit (Invitrogen
Corp.) as indicated, and was processed according to the
manufacturer’s recommendations. RNA was eluted with
50 L RNase-free water and stored at 70°C or used
immediately.
Cell Culture
Exosomes and other particulates were collected from
cells in culture as described.18 In brief, after 5 days of
culturing, the medium was collected, centrifuged at
300  g for 15 minutes, and filtered through a 0.45-m
filter to remove cell debris. The supernatant was centri-
fuged at 70,000  g to collect particulates including
exosomes, and was resuspended with 100 L PBS.
BeWo cells were purchased from American Type Culture
Collection (CCL-98; Manassas, VA) and cultured in F-12K
(Mediatech, Inc., Manassas, VA) or RPMI 1640 (HyClone
Laboratories, Inc., Logan, UT) with 10% or 20% fetal
bovine serum. To remove bovine particulates, including
exosomes, fetal bovine serum was ultracentrifuged at
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was added to culture medium. BC3 cells were cultured
as described.25
Reverse Transcription
For studies using fresh plasma, serum, and samples from
the Susan G. Komen Foundation for the Cure Tissue
Bank, 10 L of the 50 L extracted RNA was used as
input into a reverse transcriptase reaction (Superscript III;
Invitrogen Corp.) with miRNA-specific stem-loop primers
in the Duelli laboratory as described.18,26. The thermal
cycles used to amplify the samples were 65°C for 5
minutes, 50°C for 60 minutes, and 70°C for 15 minutes.
Samples from AIDS Cancer and Resource and samples
including miRNAs released from BC3 cells were ana-
lyzed using primers obtained from Applied Biosystems,
Inc. (Foster City, CA), also using miRNA-specific stem-
loop primers in the Cullen laboratory as described.26,27
MicroRNA Quantitation Using Taq-Based PCR
qPCR reactions were performed as described using
SYBR Green or TaqMan (Applied Biosystems, Inc.), as
noted.18 Four percent of the cDNA produced in the re-
verse transcriptase reaction was amplified in MicroAmp
Optical 96-well reaction plates in triplicate 20-L reac-
tions using a thermocycler (7900HT; Applied Biosystems,
Inc.) using the cycles 95°C for 10 minutes, 40 cycles at
95°C for 15 seconds, 60°C for 1 minute, and hold at 4°C.
Raw data were analyzed using SDS Relative Quantitation
Software version 2.2.3 (Applied Biosystems, Inc.), in gen-
eral using the automatic cycle threshold (Ct) setting for
assigning baseline and threshold for Ct determination.
MiRNA abundance was measured using computing amo-
les based on comparing Ct values of samples with dilu-
tions of a synthetic DNA corresponding to the cDNA
produced at reverse transcription for each miRNA mea-
sured to make a standard curve. The amplification effi-
ciency, a measure of the number of template duplications
per PCR amplification cycle, was calculated using the
equation (T2/T1)[1/(CT2ave-CT1ave)] 1.28
PCR Using Other Polymerases
GoTaq Green (Promega Corp., Madison, WI) PCR was
performed in 25-L volumes according to the manufac-
turer’s instructions. The initial denaturation step was 5
minutes at 95°C, followed by 40 cycles of 15 seconds at
95°C, 30 seconds at 50°C, 30 seconds at 72°C, and a
final extension of 5 minutes at 73°C.
Hemo KlenTaq29 (New England BioLabs, Inc., Ips-
wich, MA) PCR18 was performed in 25-L volumes ac-
cording to the manufacturer’s instructions, including at-
tempts to reduce nonspecific priming by assembling
PCR reactions on ice and transfer of reactions to the
thermocycler preheated to 95°C. PCR using cocktails
containing GoTaq DNA polymerase and Hemo
KlenTaq polymerase were performed using GoTaq
qPCR Mastermix (Promega Corp.) for SYBR Greenquantitation or TaqMan Universal PCR Mastermix (Ap-
plied Biosystems, Inc.).
Phire and Phusion enzymes were used according to
supplier specifications (New England Biolabs, Inc.) for
end-point PCR or were used with GoTaq qPCR Master-
mix (Promega Corp.) for SYBR Green or with TaqMan
Universal PCR Mastermix (Applied Biosystems, Inc.) for
quantitation.
Polyacrylamide Gel Electrophoresis
Native polyacrylamide gel electrophoresis (PAGE) of
PCR products was performed as described.18 A 10-bp
ladder (marker; Invitrogen Corp.) was used for sizing
PCR products in all experiments. Typically, 8 L of
each PCR sample was analyzed using PAGE.
Statistical Analysis
Statistical analysis was performed using one-way analy-
sis of variance followed by Tukey’s honestly significant
difference test where indicated. Column graphed data
are given as mean 1 SD. Data points were compared
using the unpaired one-tailed Student’s t-test unless oth-
erwise indicated, and P values are given in the text,
figures, or legends as are the number of independent
experiments.
Results
NaF and KOx Improve miRNA Quantitation
Various anticoagulants and blood stabilizers are used for
collection of plasma but not serum. Therefore, we tested
whether the choice of collection method affected miRNA
quantitation. Blood was collected in Vacutainer tubes
containing either an anticoagulant (EDTA, heparin, so-
dium citrate, or NaF/KOx) or no anticoagulant. Blood was
collected into the Vacutainer tubes in immediate succes-
sion using a single venipuncture per person (see Mate-
rials and Methods) to ensure nearly identical blood com-
position at the time of blood collection. Blood was drawn
from four individuals of different ethnic origin, sex, and
age on three separate dates.
miRNA abundance was measured using RT-PCR
(Figure 1A) and qPCR of reverse-transcribed miRNAs
using SYBR Green (Figure 1B). Reproducibility of miRNA
quantitation depended on the blood collection method,
with best results obtained by collecting into tubes con-
taining NaF/KOx (Figure 1B). Although in blood plasma,
miR-16 is about 500-fold more abundant than miR-223,
the recovery and accurate detection of both miRNAs
depended on the plasma collection method. Therefore,
differences in detection resulting from the choice of blood
collection method likely applies to other circulating
miRNAs regardless of abundance. Furthermore, quanti-
tation of miR-223 in serum yielded more variable results
than most other collection methods, which suggests that
at least for some miRNAs, collection of blood as plasma
and the choice of anticoagulant can improve detection.
(P 0.082) or miR-223 (P 0.125) in heparinized plasma. DNA length of the
bands in the marker is indicated by 50 and 60 bp.
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Detection after Blood Collection
Maintenance of RNA stability during and after blood col-
lection is an important factor for accurate miRNA quanti-
tation and may depend on the anticoagulant used to
collect the sample. For example, NaF/KOx is thought to
enable greater sensitivity in the quantitation of other mol-
ecules in the blood including glucose,22 alcohol, and
opioids30 by preventing their degradation at the time of
collection and during storage.31 We reasoned that the
anticoagulants may differentially affect miRNA stability
or detection by interfering with or promoting reactions
used for quantitation. Therefore, we evaluated the ef-
fect of NaF and KOx on quantitation of miRNAs col-
lected using other blood-draw methods. NaF and KOx
were added to frozen samples collected using two of
the most common blood-draw methods, that is, serum
and plasma collected into EDTA, and miR-16 was mea-
sured in these samples (see Materials and Methods). It
was observed that NaF and KOx increased miR-16
detection twofold in plasma collected using EDTA (P 
0.037), and threefold in serum (P  0.014) (Figure 2A).
These results indicate that adding NaF and KOx en-
hances miRNA quantitation even if these reagents are
added after the samples are collected using other an-
ticoagulants and stabilizers.
To address how NaF and KOx improve miRNA quan-
titation, we assessed the effects of NaF and KOx individ-
ually on miR-16 quantitation in serum. NaF increased the
mean detection of miR-16 by 2.8-fold, and KOx increased
sensitivity approximately 3.4-fold (see Supplemental
Figure S1, A and B, at http://jmd.amjpathol.org). However,
the increases lacked statistical significance for each
component alone, which suggests that NaF and KOx
synergize to effectively increase detection of miRNAs or
that they act differently in improvement of quantitation of
miRNAs in serum.
NaF and KOx Increase Detection of Exogenous
RNA
We considered that collecting plasma with NaF and KOx
can improve detection by either stabilizing the RNA or
increasing the amplification efficiency of the miRNAs dur-
ing the PCR reaction.29,32 To address the possibility that
miRNAs are degraded by plasma ribonucleases,33 we
quantified miRNA stability before miRNA extraction by
comparing endogenous miR-16 concentrations with
those of a synthetic 22-nucleotide RNA (SYNTH) added
during the RNA extraction. It was observed that the quan-
tity of RNA was similar for both SYNTH RNA and endog-
enous miR-16 for each of the Vacutainer tubes (Figure
2B), which suggests that factors other than RNA stability
in serum or plasma account for the differences in the
sensitivity of RNA quantitation. Therefore, we tested
whether the collection method affects PCR amplification
efficiency. No significant changes were detected in the
amplification efficiencies induced by the blood stabilizersFigure 1. Fluoride and oxalate increase quantitation efficiency of circulating miR-
NAs. A: MiR-16 detection is affected by the blood collection method. Plasma and
serum samples were collected from four individuals on three occasions. MiR-16 was
amplified using RT-PCR, and was separated using PAGE. Arrow, miR-16 as deter-
mined by sizing and sequencing. B: Collection of blood in the presence of EDTA,
citrate, orNaF/KOx increasesmiRNAdetection.MiR-16 andmiR-223werequantified
using SYBR Green RT-qPCR approaches. Data were analyzed using one-way anal-
ysis of variance followed by Tukey’s honestly significant difference test. Middle bar
represents the median; top and bottom of the box represent the 75th and 25th
percentiles, respectively. Tukey’s fences indicate the range of the values. P
values are labeled above or below brackets. Chemicals listed indicate the
coagulant and/or blood stabilization agents present in the particular Vacu-
tainer tube used for the blood collection (see Materials and Methods).
Heparinase indicates addition of heparinase I to the sample (see Materials
and Methods). Lower panel: MiR-223 detection is robust in NaF/KOx.
Detection of miR-16 or miR-223 was less in heparinized plasma than in
serum. Heparinase treatment did not always improve detection of miR-16or anticoagulants (Figure 2C). We concluded from this
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PCR amplification of reverse-transcribed miRNAs per se.
Hence, NaF and KOx may improve miRNA detection by
Figure 2. Fluoride and oxalate improve detection of RNA regardless of
origin. A: NaF/KOx was added at indicated concentrations to 50 L-serum
and plasma samples collected in EDTA. MiR-16 detection at both concentra-
tions was increased (P  0.014 in serum, and P  0.037 in EDTA plasma).
There was no statistical difference between the two concentrations of NaF/
KOx (P  0.827 for serum, and P  0.275 for EDTA plasma) (n  3). B:
Synthetic RNA (SYNTH) was added at 250 fmol/L during addition of TRIzol
to the serum samples or plasma collected using indicated additives. The
effectiveness of SYNTH quantitation was compared with that of endogenous
miR-16. C: Amplification efficiency of miR-16 and SYNTH in qPCR was
measured and compared with that of serum. For miR-16: heparin, P  0.58;
heparin plus heparinase, P  0.43; EDTA, P  0.41; citrate, P  0.52; and
KOx, P  0.43. For SYNTH: heparin, P  0.53; heparin plus heparinase, P 
0.49; EDTA, P  0.63; Citrate, P  0.41; and KOx, P  0.47. (All n  3.)enhancing miRNA yield during extraction by enhancingthe reverse transcriptase reaction or perhaps in general
by stabilizing the extracted RNA or the cDNA.
The finding of strong parallels between SYNTH and
miR-16 quantitation within each plasma and serum sam-
ple supports the convention of using exogenous spiked
RNAs as reference molecules for quantifying miRNA in
plasma and serum. Alternatively, it was observed that
quantitation of SYNTH added in a 4000-fold excess was
much less affected by most collection methods (see Sup-
plemental Figure S2 at http://jmd.amjpathol.org). This re-
sult suggests that high concentrations of RNA can
overcome the interference of plasma components on
miRNA quantitation and highlights the need to supply
spiked RNA at similar concentrations as the endoge-
nous RNA under investigation for accurate reference
quantitation.
Inhibitors of Polymerases Present in Biological
Samples Affect miRNA Detection
To assess the stability of miRNAs in blood, we added
released miRNAs isolated from the media of cultured
BC3 cells to PBS, plasma, and whole blood. It was ob-
served that miR-16 could be detected up to 17 hours
after addition to PBS but was undetectable in plasma
after 2 hours or in whole blood after 17 hours of storage
(Figure 3A). This destabilization effect could be due to
miRNA degradation in the sample,34 to components of
blood plasma that co-purify with miRNAs and interfere
with their detection,29,35–37 or to both.
Therefore, we tested whether plasma RNA interferes
with the detection of SYNTH RNA. SYNTH RNA was sup-
plemented with TRIzol-extracted RNA preparations of
plasma collected in EDTA Vacutainer tubes, and SYNTH
RNA abundance was quantified (Figure 3B, left panel). It
was observed that RNA extracted from blood plasma
interfered with SYNTH RNA detection, indicating that in-
hibitors of reverse transcriptase or PCR are present in
RNA preparations extracted using TRIzol alone.
To determine the best method for removing serum and
plasma inhibitors of miRNA detection, we applied ap-
proaches to improve the purity of the isolated RNA. It was
observed that incorporation of a single acidic phenol/
chloroform extraction step followed by adsorption of RNA
on silica membranes reduced the interference by blood-
borne polymerase inhibitors (Figure 3B, right panel) and
effected a 4.4-fold increase in miRNA quantitation
(Figure 3C). Other treatments such as addition of deter-
gents38 or ribonuclease inhibitors did not improve miRNA
detection in serum or plasma (see Supplemental Figure
S3 at http://jmd.amjpathol.org), which suggests that com-
ponents other than ribonucleases or other proteins were
responsible for the interference. We concluded that en-
richment of small RNAs using TRIzol and phenol/chloro-
form extractions and silica adsorption effectively remove
blood-borne reverse transcriptase and/or PCR inhibitors
that prevent accurate quantitation of miRNAs in blood
plasma.
re separ
storage
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The presence of inhibitors of miRNA detection in blood
suggests that the greater the plasma or serum starting
material used to extract the miRNA, the greater the abun-
dance of co-purified blood-borne inhibitors of RT-PCR.
Thus, we tested whether dilution of starting material af-
fects the efficiency of detection. To do so, we quantified
miRNA extracted from 10, 50, or 200 L fresh serum or
plasma. It was observed that 50 L serum improved
detection of miRNA by end-point PCR (Figure 3D) and
yielded an 11-fold increase in the sensitivity of miRNA
detection using SYBR Green or TaqMan qPCR
(Figure 3E), perhaps reflecting a balance between
miRNA and inhibitor abundance. To test whether similar
concentration effects also apply to stored samples, we
tested plasma collected in EDTA Vacutainer tubes from
patients infected with HIV and Kaposi’s sarcoma–asso-
ciated herpesvirus and stored for several months. It was
observed that, similar to fresh samples, detection of
miR-16 abundance was about threefold more sensitive at
50 L than at 10 or 200 L (Figure 3E). These data are
consistent with the counterintuitive idea that using more
blood for detecting miRNA results in less efficient detec-
tion than using less blood. Because this effect was ob-
served in both plasma and serum, the latter of which is
collected in the absence of additives, we concluded that
inhibitors of miRNA detection are inherent in blood rather
Figure 3. Removal of blood plasma and serum components that inhibit dete
A: Particulate miR-16 released from cells and added to plasma or whole blo
incubated in PBS, plasma, or blood for the indicated time, and miR-16 was
likely of whole-blood origin. B: Phenol/chloroform extraction and silica abso
collected in EDTA using TRIzol only (left panel) or TRIzol followed by one e
(right panel), and cDNA was added to a standard PCR reaction to quantify
reaction (indicated by “1” above the gel), and 10-fold dilutions thereof
phenol/chloroform and silica absorption. Plasma preparations were extracted
to silica, or were directly assessed using RT-qPCR. D and E: Low volumes o
extracted using TRIzol were subjected to end-point PCR for miR-16, and we
MiR-16 was quantified in EDTA plasma immediately after collection or afterthan introduced by chemicals used for collection. Of im-portance, by reducing the starting material, inhibitors
were presumed to be diluted below a threshold of inter-
ference. Thus, careful titration of starting material yields
more accurate miRNA quantitation.
Heparinase Treatment of Plasma Increases
miRNA Detection
Heparin is an endogenous component of blood and is
one of the original anticoagulants used in medicine. In
some instances such as when analyzing historical sam-
ples or evaluating the blood of patients receiving heparin
regimens because of deep venous thrombosis, stroke, or
pulmonary embolism or during organ transplantation or
heart surgery, heparinized plasma may be the only
source of miRNA. In these cases, it is important to eval-
uate the effect of heparin on miRNA quantitation. We
observed that miRNA quantified from heparinized plasma
gave a poor yield (Figure 1), consistent with RT-PCR
inhibition by heparin.39 In testing whether reducing the
starting volume could improve detection, we observed
that using less starting material enabled detection of
miR-16 from heparinized blood. However, greater dilu-
tions were required to effect similar detection as in
plasma collected using other methods (compare
Figures 3D and Figure 4A). Therefore, we tested whether
miRNA detection can be improved by digesting heparin
with lyase heparinase I before RT-PCR.24,40 This treat-
circulating MiRNA using organic extraction and silica-based RNA enrichment.
t detectable within 17 hours. Particulate RNAs released from BC3 cells was
d using TaqMan RT-qPCR. Portions of miR-16 in 2-hour blood samples are
f RNA remove inhibitors of miRNA detection. RNA was isolated from plasma
n of phenol/chloroform and enrichment of small RNAs on a silica membrane
RNA. RNA was added at the same concentration used in a standard RT-qPCR
102, 103). C: Enhanced detection of miR-16 in plasma extracted via
ndicated numbers of phenol/chloroform extractions, followed by absorption
a or serum effect greater detection of miRNAs. Indicated volumes of serum
ated using PAGE. Solid circles indicate amplification-independent products.
at 80°C.ction of
od is no
quantifie
rption o
xtractio
SYNTH
(101,
using i
f plasmment enabled detection and quantitation of previously
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that heparinase can increase detection of miRNAs in
heparinized plasma. These results suggest that, when
possible, heparin tubes should not be used in miRNA
analysis. Alternatively, heparinase treatment provides an
approach to detection of miRNAs when use of heparin is
unavoidable or when heparin is present in previously
collected samples.
Figure 4. Heparin interference with detection of miRNA is relieved via
heparinase treatment. Plasma was collected in Vacutainer tubes containing
sodium heparin, and indicated volumes of plasma were assessed using
end-point PCR (A). RT-PCR was performed after treatment with heparinase I
() or on RNA without heparinase treatment (). PCR products for miR-16
(B) and miR-223 (C) were assessed using PAGE.
Figure 5. Mutant TaqDNA polymerase, Hemo KlenTaq improves the sen
(arrows) in 200, 50, and 10 L plasma and serum (see Figure 3C). Ad
reverse-transcribed miR-16 in serum or NaF/KOx plasma and using an inta
amplified with HKi or i from six individuals (1 to 6). D: Absolute quantitation of
multiple comparisons test).Mutant TaqDNA Polymerase Improves
Quantitation of miRNA
An alternative approach to avert interference from blood-
borne inhibitors of RT-PCR is to use different poly-
merases 29,35–37,41. We tested enzymes reported to be
more resistant to inhibitors: Phusion, Phire, and Hemo
KlenTaq. Hemo KlenTaq is a mutant Taq DNA polymer-
ase that has 100-fold lower sensitivity to blood inhibitors
than does wild-type Taq.29 Our analysis indicates that
Hemo KlenTaq amplified miR-16, more efficiently than
did Phusion (Figure 5A; see also Supplemental
Figure S4A at http://jmd.amjpathol.org), and standard Taq
DNA polymerase yielded low or no detectable PCR prod-
ucts in the same samples (Figure 3D). However, initial
attempts to adopt these enzymes for qPCR of miRNAs
using TaqMan failed (see Supplemental Figure S4B at
http://jmd.amjpathol.org). It is likely that for Hemo
KlenTaq, quantitation was compromised by production of
multiple spurious bands in addition to the correct band
(Figure 5A; see also Supplemental Figure S4 at http://
jmd.amjpathol.org). We tested whether this lack of spec-
ificity is a general property of Hemo KlenTaq by evaluat-
ing the purity of amplifying miR-16 released from BeWo
cells in culture. We detected only the correct miR-16 PCR
product. However, supplementing such PCR reactions
with blood plasma cDNA was sufficient to give rise to the
of miRNA detection. A: Hemo KlenTaq (HK) was used to detect miR-16
PCR products are indicated by a star. B: TaqMan qPCR of dilutions of
olymerase (i) plus Hemo KlenTaq (HKi) as indicated. C: PAGE of miR-16sitivity
ditional
ct Taq pmiR-16 amplification products. **P  0.01; ***P  0.001 (Tukey-Kramer
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further before PCR amplification (see Supplemental Fig-
ure S5 at http://jmd.amjpathol.org). This finding suggests
that the complexity or other properties of blood cDNA
interfere with exclusive amplification of the miRNAs of
interest and cause nonspecific cDNA amplification. This
phenomenon may be a consequence of lack of the edit-
ing and proofreading 5=-3= exonuclease domain in
Hemo KlenTaq.32
Complementing Enzyme Cocktail for Effective
Amplification of Products
To overcome the limitations of Hemo KlenTaq, we tested
whether the reduced proof-reading activity of Hemo
KlenTaq could be complemented by an intact Taq poly-
merase. It was observed that Hemo KlenTaq in combi-
nation with intact Taq polymerases amplified specific
PCR products suitable for qPCR using SYBR Green or
TaqMan (Figures 5, B and C; see also Supplemental
Figure S6A at http://jmd.amjpathol.org). Of importance,
the complementing Taq polymerases produced, on av-
erage, approximately 30-fold more amplification prod-
ucts from plasma miR-16 than did the intact polymerase
alone (see Supplemental Figure S6B at http://jmd.
amjpathol.org), which suggests that overcoming blood-
borne inhibitors of Taq polymerase using Hemo KlenTaq
yields an overall increase in detection sensitivity and
specificity of circulating miRNAs.
Mir-16 Quantitation Sensitive to Method of
Detection
To test whether overcoming endogenous inhibitors with
complementing polymerases provides proportionally
Table 1. Effectiveness of Various Treatments in miRNA Detectio
Treatment/approach Sensitivity*
Choice of anticoagulant and stabilizer
NaF/KOx 2.7
EDTA 1.1
Citrate 1.7
Heparin 0.3
Serum 1
NaF/KOx after collection 3.6§
Starting volume (L)
10 1
50 11¶
200 0.7
Silica/phenol/chloroform 4.4
Hemo KlenTaq/GoTaq 30
Heparinase 2**
*Approximate fold difference in detected abundance compared with
†Material cost per sample, calculated as percent of total cost of serum
in the study, which was $9.25 for triplicate TaqMan.
‡Increase in sensitivity returned per material investment.
§2.4-Fold when supplemented to EDTA plasma.
¶Threefold in frozen samples.
Extra total time spent on adsorption per sample is gained by elimin
method. However, there is an increase in active labor, which, depending
**Fold of plasma collected in heparin. Ranges from statistically nonsignifican
(Figure 4).higher miRNA quantitation, we analyzed circulating
miRNAs in the blood of six healthy individuals (see Sup-
plemental Figure S7 at http://jmd.amjpathol.org). Five of
the six individuals tested demonstrated similar miR-16
plasma concentrations regardless of the approach used,
thus validating the use of complementing enzymes for
improved detection of circulating miRNAs. With each
approach, one individual consistently exhibited higher
plasma miR-16 abundance than did the others (Figure
5D). However, another individual in either approach
exhibited higher miR-16 concentrations, which sug-
gests that quantitation of circulating miR-16, which is
used as a reference miRNA or a biomarker of some
cancers,16–19 depends on the PCR conditions. These
results suggest that differences in plasma composition
among individual donors can yield different miRNA
measurements.
Discussion
This study demonstrates that inherent differences in bio-
logical samples and the methods used to collect and
analyze them can dramatically affect the detection and
quantitation of miRNAs. The implications of the work are
that without consideration of the variables we have iden-
tified, miRNA quantitation of human samples may not be
reliable for the purpose of biomarker development. Our
results suggest that failure to detect plasma miRNAs may
be due to polymerase inhibitors rather than to the ab-
sence of miRNA. Such inhibitors may include hemoglo-
bin,42 lactoferrin,36 and IgG,43 which can co-purify with
nucleic acids.37 This limitation can be overcome with
concomitant use of two complementing Taq poly-
merases: Hemo KlenTaq, which is resistant to blood-
borne inhibitors, in combination with another intact poly-
ra time
sample
Cost
(%)†
Sensitivity/
cost‡ Figure
0 99 2.7 1
0 99 1.1 1
0 100 1.7 1
0 101 0.3 1
0 100 1.0 1
onds 100 3.6 2A
0 100 1.0 3, D and E; 4A
0 100 11 3, D and E; 4A
0 100 0.7 3, D and E; 4A
inutes 181 2.4 3, B and C
onds 101 30 5
our 130 1.5 1 and 4
iR-16.
6 detection using TaqMan, in $US, based on list price of materials used
the chilling step for precipitation of RNA (1 hour) using the standard
number of samples processed, may by substantial.n
Ext
per
Sec
11 m
Sec
1 H
serum m
miR-1
ation of
on thet changes (Figure 1) to detecting signal only after heparinase treatment
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JMD January 2012, Vol. 14, No. 1merase that has effective proofreading ability. In addition,
the study demonstrates that diluting out inhibitors from
blood samples also provides salient improvements in
miRNA detection (Table 1). Additional purification of
plasma or serum miRNA preparations, using organic ex-
traction and silica adsorption to remove inhibitors, also
increased the detection, albeit at greater cost in labor
and funds.
The inability to detect specific miRNAs in plasma or
serum, in many cases, reflects the low abundance of
particular miRNAs in the circulation. For example, the
release of some miRNAs from cells into blood is limited or
selective.18,44,45 Furthermore, depending on the nature
of the complex that circulating miRNAs are associated
with,18,34,46–52 some miRNAs may be more stable than
others34 to the degradation by plasma ribonucleases or
may be more amenable to amplification by polymerases.
When usual techniques fail, the improvements outlined
herein enable quantitation of miRNAs with low abun-
dance and are expected to increase the repertoire of
miRNAs that can be analyzed as potential biomarkers of
disease.
The mechanism by which some of the approaches, for
example, use NaF/KOx, improve detection is unclear. It is
possible that NaF effects higher cDNA stability during the
reverse transcriptase reaction, rather than stabilizing in-
put miRNA, because classic experiments identified NaF
as an inhibitor of RNase H,53 an enzyme that degrades
RNA and DNA hybrid substrates. However, KOx may
promote miRNA detection by reducing calcium, an inhib-
itor of Taq, in the blood sample.41
Of interest, the absolute quantity of circulating miR-16
measured in the blood of some individuals differed de-
pending on the enzyme used. These differences raise the
possibility that factors including diet,54 exercise,55 circa-
dian rhythms,56 and seasons,57,58 which alter the blood
chemistry, might ultimately affect miRNA detection and
quantitation. The disparate effectiveness of miRNA de-
tection in an individual’s plasma or serum may be indic-
ative of other physiologic and pathogenic properties of
the blood including endogenous heparin concentra-
tions59 or familial disease.60 Our results demonstrate that
such variations in blood chemistry can affect detection of
miRNAs and must be considered and neutralized to ac-
curately and efficiently assess miRNA abundance in
blood serum and plasma.
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